Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Germany's Siemens to set out plan for $41 billion Healthineers stake
    Finance

    Germany's Siemens to set out plan for $41 billion Healthineers stake

    Published by Global Banking & Finance Review®

    Posted on November 10, 2025

    4 min read

    Last updated: January 21, 2026

    Germany's Siemens to set out plan for $41 billion Healthineers stake - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:investmentfinancial managementcorporate governanceMergers and Acquisitions

    Quick Summary

    Siemens plans to reduce its $41 billion Healthineers stake, potentially enhancing its M&A capabilities and focusing on AI and industrial software.

    Siemens Plans Major Reduction of $41 Billion Healthineers Stake

    By John Revill

    ZURICH (Reuters) -German engineering group Siemens is expected to set out how it will cut its 35 billion euro ($41 billion) Siemens Healthineers stake on Thursday.

    A sizeable disposal, which would dwarf recent divestments such as SoftBank selling part of T-Mobile for $4.8 billion, would give Siemens CEO Roland Busch financial firepower to pursue M&A.

    CFO Ralf Thomas said last year that Siemens would present its decision on Healthineers at its capital markets day, which takes place this week.

    Siemens listed the maker of medical imaging and diagnostics equipment in 2018 but kept an initial 85% stake. It has since gradually cut its holding, selling 2% for around 1.45 billion euros in February.

    Deka Investment, a top 15 Siemens shareholder, wants it to reduce the stake from just below 70% now to 51%, before possibly further reducing the Healthineers holding.

    Ingo Speich, Deka's head of sustainability and corporate governance, said it was chance for Busch, 60, to focus Siemens more on artificial intelligence and industrial software.

    CEO'S CHANCE TO SHAPE LEGACY

    Busch, whose contract runs until 2030, has led Siemens since 2021 and decisive moves could shape his legacy, Speich said.

    "This is probably the last term for Busch. He's delivered decent earnings but he hasn't really left a major footprint where he shaped Siemens for the next decade," he told Reuters.

    Another large Siemens investor, who asked not to be named, also wants Siemens to cut its Healthineers stake below 50% over the next few years, with a gradual selldown.

    "The most important decision on Thursday will be what happens with Healthineers," said the investor.

    Siemens declined to comment on its plans or a Bloomberg report that it would reduce its stake to below 40% by giving its shareholders Healthineers stock.

    EXIT WOULD BOOST M&A FIREPOWER

    Although Healthineers is regarded as a good quality business, exiting would allow Siemens to focus on areas such as industrial software and automation.

    It would also give it more scope to pursue acquisitions that deepen capabilities that complement its hardware range, which includes factory controllers and sensors.

    "It's logical to use the money raised from Healthineers in a different way, either by giving it to shareholders, or as an acquisition currency," said Deka's Speich.

    "Busch wants a strong Siemens to avoid any takeover rumours and it's important to have a large Siemens with the financial power for large acquisitions," he said.

    Analysts say exiting will be complex and could take years.

    THREE LIKELY OPTIONS FOR REDUCING STAKE

    Siemens would most likely pursue one of three options, Barclays' Vlad Sergievskii said.

    It could give Healthineers shares to its investors as a dividend in kind, transfer them to a separate holding vehicle and spin this off to shareholders or gradually sell the stake, he said.

    If Siemens distributed two thirds of its Healthineers stake as a dividend in kind, it would have to pay 7 billion euros in German tax, said JP Morgan, adding: "There are smarter ways to structure a process like this".

    Giving away the shares directly or indirectly through a new company would not generate money for Siemens and would end up creating a secondary Healthineers listing.

    Meanwhile, a sell down could be a lengthy process as Siemens would have to avoid driving down the share price by landing large volumes on the market.

    Siemens shares have gained 31% in 2025, outperforming the Stoxx Europe Industrial Goods & Services index, which gained 21%. Healthineers, whose stock has been weighed down by uncertainty over Siemens' stake, has lost 15%.

    "All three approaches have pros and cons," said Barclays' Sergievskii.

    ($1 = 0.8575 euros)

    (Reporting by John Revill; Editing by Alexander Smith)

    Key Takeaways

    • •Siemens plans to reduce its Healthineers stake significantly.
    • •The divestment could enhance Siemens' M&A capabilities.
    • •CEO Roland Busch aims to focus on AI and industrial software.
    • •Three potential strategies for stake reduction are considered.
    • •Healthineers' stock has been affected by Siemens' stake decisions.

    Frequently Asked Questions about Germany's Siemens to set out plan for $41 billion Healthineers stake

    1What is a merger and acquisition?

    A merger and acquisition (M&A) refers to the consolidation of companies or assets through various types of financial transactions, including mergers, acquisitions, and consolidations.

    2What is a financial strategy?

    A financial strategy is a plan that outlines how an organization will manage its financial resources to achieve its goals and objectives.

    3What is an investment?

    An investment is an asset or item acquired with the goal of generating income or appreciation. It can include stocks, bonds, real estate, and other financial instruments.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostCritics call proposed changes to landmark EU privacy law 'death by a thousand cuts'
    Next Finance PostTesla's Model Y program manager announces exit alongside Cybertruck lead